FLOTRENIZINE, a diarylmethylpiperazine derivative, is an antihistaminic agent.

Nicoclonate is a nicotinic acid derivative. It is an antilipidemic drug.

Silydianin is a flavonolignan from Silymarin, which is the major constituent of milk thistle extract. Silydianin, an active constituent of Silybium marianum, have inhibitory properties against the P2Y12 receptor and block ADP-induced blood platelet activation. Silydianin has antiinflammatory activity, it regulates caspase-3 activation, affects cell membranes and acts as a free radical scavenger. Silydianin non-competitively inhibits the lipoxygenase from soybeans in vitro. It also inhibits the formation of prostaglandins in vitro.

Doxpicomine is the hydrochloride salt of l-3[(dimethylamino)-(m-dioxan-5-yl)methyl]pyridine, a derivative of substituted 1,3 dioxanes. Its analgesic effect appears to be mediated centrally through opiate-like receptors. Preclinical animal studies revealed analgesic activity and duration of action of the same order as that of meperidine and codeine when administered subcutaneously and of codeine but of shorter duration when administered orally. The analgesic effects were reversed by naloxone. The drug did not reduce or antagonize the analgesic effect of morphine. Drowsiness is an expected response to effective analgesics. It was the foremost side effect observed but was of short duration and minimal intensity and did not interfere with the postoperative regimen of coughing, deep breathing, and early ambulation. Nausea and vomiting were not reported after doxpicomine.

FLUMEXADOL is a non-opioid analgesic. Its prodrug OXAFLOZANE was used as an antidepressant in France till 2004.

Pipramadol is an analgesic agent. Pipramadol exhibits not only antinociceptive but also central and peripheral antiserotonin properties.

Nemorubicin, a doxorubicin derivative, is a DNA-intercalator, topoisomerase and RNA synthesis inhibitor that was undergoing development with Nerviano Medical Sciences (Nerviano MS; formerly Pharmacia Italia) for the treatment of solid tumours, specifically, the loco-regional treatment of primary liver tumours (hepatocellular carcinoma). The drug is active on tumors resistant to alkylating agents, topoisomerase II inhibitors and platinum derivatives. It works primarily through topoisomerase I inhibition. Of note, Nemorubicin is active in cells with upregulation of the nucleotide excision repair (NER) pathway, where current therapies fail. Nemorubicin is biotransformed in the liver into cytotoxic metabolites that may further contribute to render this drug highly active against primary liver tumors or liver metastases. Clinical trials were conducted in Europe, US and China with Nemorubicin given at different dose-schedules and by different routes of administration: as single agent by systemic IV route, oral route and by intra-hepatic artery (IHA) infusion alone or in combination with cisplatin.

Olmidine (also known as dl-mandelamidine) is an antihypertensive drug that has never been marketed. Information about the current use of this drug is not available.